Use of Win Statistics to Analyze Outcomes in the DAPA-HF and DELIVER Trials-Reference-Cited by-同舟云学术

Use of Win Statistics to Analyze Outcomes in the DAPA-HF and DELIVER Trials

Published:2023-10-24 Issue:11 Volume:2 Page:
ISSN:2766-5526
Container-title:NEJM Evidence
language:en
Short-container-title:NEJM Evidence

Author:

Kondo Toru¹²,Gasparyan Samvel B.³,Jhund Pardeep S.¹,Bengtsson Olof³,Claggett Brian L.⁴,de Boer Rudolf A.⁵,Hernandez Adrian F.⁶,Inzucchi Silvio E.⁷,Kosiborod Mikhail N.⁸,Køber Lars⁹,Lam Carolyn S.P.¹⁰,Langkilde Anna Maria³,Martinez Felipe A.¹¹,Petersson Magnus³,Ponikowski Piotr¹²,Sabatine Marc S.¹³,Shah Sanjiv J.¹⁴,Sjostrand Mikaela³,Wilderang Ulrica³,Vaduganathan Muthiah⁴,Solomon Scott D.⁴,McMurray John J.V.¹

Affiliation:

1. British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom

2. Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya, Japan

3. Late-Stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden

4. Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School, Boston

5. University of Groningen, Groningen, the Netherlands

6. Duke University Medical Center, Durham, NC

7. Yale School of Medicine, New Haven, CT

8. Saint Luke’s Mid America Heart Institute, Kansas City, MO

9. Department of Cardiology, Copenhagen University Hospital–Rigshospitalet, Copenhagen

10. National Heart Centre Singapore & Duke-National University of Singapore, Singapore

11. University of Cordoba, Cordoba, Argentina

12. Department of Heart Disease, Wroclaw Medical University, Wroclaw, Poland

13. TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women’s Hospital, Boston

14. Northwestern University Feinberg School of Medicine, Chicago

Publisher

Massachusetts Medical Society

Reference41 articles.

1. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

2. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure

3. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

4. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

5. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Basic Data Structure for Hierarchical Composite Endpoints: An Application to Kidney Disease Trials;Journal of the Society for Clinical Data Management;2024-02-08